AMIC-话题@MedSci - 梅斯（MedSci）

#AMIC#

15篇内容 | 766人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1779874, encodeId=6efc1e7987496, content=<a href='/topic/show?id=43df242149' target=_blank style='color:#2F92EE;'>#AMIC#</a>, objectTitle=NEJM：ctDNA可能指导II期结直肠癌的后续化疗（DYNAMIC研究）, objectType=article, longId=729912, objectId=4c07e2991275, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4c07e2991275, replyNumber=0, likeNumber=81, createdTime=2022-10-01, rootId=0, userName=yhy100200, userId=cc52251, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4c07e2991275, moduleTitle=NEJM：ctDNA可能指导II期结直肠癌的后续化疗（DYNAMIC研究）, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=4c07e2991275)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1779873, encodeId=a1161e7987340, content=<a href='/topic/show?id=43df242149' target=_blank style='color:#2F92EE;'>#AMIC#</a>, objectTitle=JCO：Gemtuzumab Ozogamicin可改善KMT2A重排型AML患儿预后、减少复发！, objectType=article, longId=212166, objectId=c8ad21216642, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c8ad21216642, replyNumber=0, likeNumber=67, createdTime=2021-10-08, rootId=0, userName=yhy100200, userId=cc52251, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c8ad21216642, moduleTitle=JCO：Gemtuzumab Ozogamicin可改善KMT2A重排型AML患儿预后、减少复发！, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c8ad21216642)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1779872, encodeId=eea81e798723b, content=<a href='/topic/show?id=43df242149' target=_blank style='color:#2F92EE;'>#AMIC#</a>, objectTitle= Blood：Inotuzumab ozogamicin用于复发/难治性小儿急性淋巴细胞白血病的疗效, objectType=article, longId=209725, objectId=06c7209e2530, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=06c7209e2530, replyNumber=0, likeNumber=89, createdTime=2021-12-25, rootId=0, userName=yhy100200, userId=cc52251, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=06c7209e2530, moduleTitle= Blood：Inotuzumab ozogamicin用于复发/难治性小儿急性淋巴细胞白血病的疗效, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=06c7209e2530)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1779871, encodeId=f34e1e79871b9, content=<a href='/topic/show?id=43df242149' target=_blank style='color:#2F92EE;'>#AMIC#</a>, objectTitle=Blood：Getuzumab ozogamicin治疗对NPM1突变AML患者MRD和复发风险的影响, objectType=article, longId=200012, objectId=052a20001262, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=052a20001262, replyNumber=0, likeNumber=88, createdTime=2021-06-26, rootId=0, userName=yhy100200, userId=cc52251, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=052a20001262, moduleTitle=Blood：Getuzumab ozogamicin治疗对NPM1突变AML患者MRD和复发风险的影响, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=052a20001262)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1779870, encodeId=9c371e798706a, content=<a href='/topic/show?id=43df242149' target=_blank style='color:#2F92EE;'>#AMIC#</a>, objectTitle=复发难治性ALL的挽救治疗：低强度化疗联合Inotuzumab Ozogamicin, objectType=article, longId=179545, objectId=cf0e1e95458e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf0e1e95458e, replyNumber=0, likeNumber=150, createdTime=2019-12-27, rootId=0, userName=yhy100200, userId=cc52251, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf0e1e95458e, moduleTitle=复发难治性ALL的挽救治疗：低强度化疗联合Inotuzumab Ozogamicin, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=cf0e1e95458e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1779867, encodeId=16041e7986767, content=<a href='/topic/show?id=43df242149' target=_blank style='color:#2F92EE;'>#AMIC#</a>, objectTitle=美国FDA向Amicus的AT-GAA治疗迟发型庞贝氏病授予了突破性治疗指定, objectType=article, longId=161117, objectId=2dcd16111ee7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2dcd16111ee7, replyNumber=0, likeNumber=74, createdTime=2019-07-15, rootId=0, userName=yhy100200, userId=cc52251, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2dcd16111ee7, moduleTitle=美国FDA向Amicus的AT-GAA治疗迟发型庞贝氏病授予了突破性治疗指定, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=2dcd16111ee7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1779865, encodeId=3d441e7986538, content=<a href='/topic/show?id=43df242149' target=_blank style='color:#2F92EE;'>#AMIC#</a>, objectTitle=Amicus的Galafold在美国获批, objectType=article, longId=146615, objectId=00741466151d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=00741466151d, replyNumber=0, likeNumber=57, createdTime=2018-09-17, rootId=0, userName=yhy100200, userId=cc52251, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=00741466151d, moduleTitle=Amicus的Galafold在美国获批, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=00741466151d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1779868, encodeId=37881e79868aa, content=<a href='/topic/show?id=43df242149' target=_blank style='color:#2F92EE;'>#AMIC#</a>, objectTitle=！Amicus庞培病疗法获突破性疗法认定, objectType=article, longId=161370, objectId=38be1613e074, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=38be1613e074, replyNumber=0, likeNumber=96, createdTime=2019-10-15, rootId=0, userName=yhy100200, userId=cc52251, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=38be1613e074, moduleTitle=！Amicus庞培病疗法获突破性疗法认定, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=38be1613e074)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1779869, encodeId=95d11e7986946, content=<a href='/topic/show?id=43df242149' target=_blank style='color:#2F92EE;'>#AMIC#</a>, objectTitle=药明生物祝贺Amicus新一代庞贝氏症疗法获FDA突破性疗法认定, objectType=article, longId=161438, objectId=c9f2161438db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c9f2161438db, replyNumber=0, likeNumber=82, createdTime=2019-12-24, rootId=0, userName=yhy100200, userId=cc52251, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c9f2161438db, moduleTitle=药明生物祝贺Amicus新一代庞贝氏症疗法获FDA突破性疗法认定, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c9f2161438db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1779866, encodeId=fa4e1e79866b2, content=<a href='/topic/show?id=43df242149' target=_blank style='color:#2F92EE;'>#AMIC#</a>, objectTitle=FDA拒绝加速审批Amicus公司的庞贝病新药AT-GAA, objectType=article, longId=148612, objectId=bd9f14861215, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bd9f14861215, replyNumber=0, likeNumber=78, createdTime=2019-02-10, rootId=0, userName=yhy100200, userId=cc52251, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bd9f14861215, moduleTitle=FDA拒绝加速审批Amicus公司的庞贝病新药AT-GAA, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=bd9f14861215)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1779864, encodeId=b0b61e798642d, content=<a href='/topic/show?id=43df242149' target=_blank style='color:#2F92EE;'>#AMIC#</a>, objectTitle=J Endod：单锥核技术辅以Endosequence Bioceramic封闭剂的非手术根管治疗的临床效果观察, objectType=article, longId=135546, objectId=b8e1135546c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b8e1135546c0, replyNumber=0, likeNumber=92, createdTime=2018-06-10, rootId=0, userName=yhy100200, userId=cc52251, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b8e1135546c0, moduleTitle=J Endod：单锥核技术辅以Endosequence Bioceramic封闭剂的非手术根管治疗的临床效果观察, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=b8e1135546c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1779862, encodeId=21ed1e798624a, content=<a href='/topic/show?id=43df242149' target=_blank style='color:#2F92EE;'>#AMIC#</a>, objectTitle=Amicus Therapeutics法布里病新药Galafold获英国NICE支持批准, objectType=article, longId=80709, objectId=43e080e0996, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43e080e0996, replyNumber=0, likeNumber=98, createdTime=2017-01-21, rootId=0, userName=yhy100200, userId=cc52251, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43e080e0996, moduleTitle=Amicus Therapeutics法布里病新药Galafold获英国NICE支持批准, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=43e080e0996)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1779861, encodeId=2d1b1e79861ee, content=<a href='/topic/show?id=43df242149' target=_blank style='color:#2F92EE;'>#AMIC#</a>, objectTitle=NEJM：Inotuzumab ozogamicin治疗ALL效果显著, objectType=article, longId=70668, objectId=2b3ee06689d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2b3ee06689d, replyNumber=0, likeNumber=80, createdTime=2016-12-31, rootId=0, userName=yhy100200, userId=cc52251, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2b3ee06689d, moduleTitle=NEJM：Inotuzumab ozogamicin治疗ALL效果显著, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=2b3ee06689d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1779860, encodeId=96f51e79860c4, content=<a href='/topic/show?id=43df242149' target=_blank style='color:#2F92EE;'>#AMIC#</a>, objectTitle=EHA 2016：辉瑞ADC药物inotuzumab ozogamicin治疗CD22阳性急性淋巴细胞白血病（ALL）表现出强劲疗效, objectType=article, longId=70650, objectId=3744e0650f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3744e0650f8, replyNumber=0, likeNumber=89, createdTime=2016-09-24, rootId=0, userName=yhy100200, userId=cc52251, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3744e0650f8, moduleTitle=EHA 2016：辉瑞ADC药物inotuzumab ozogamicin治疗CD22阳性急性淋巴细胞白血病（ALL）表现出强劲疗效, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=3744e0650f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1779863, encodeId=13211e7986321, content=<a href='/topic/show?id=43df242149' target=_blank style='color:#2F92EE;'>#AMIC#</a>, objectTitle=罕见病新药递送！英国NICE批准Amicus公司法布里病新药Galafold, objectType=article, longId=86732, objectId=94fe86e32bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94fe86e32bc, replyNumber=0, likeNumber=62, createdTime=2017-09-30, rootId=0, userName=yhy100200, userId=cc52251, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94fe86e32bc, moduleTitle=罕见病新药递送！英国NICE批准Amicus公司法布里病新药Galafold, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=94fe86e32bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

AMIC

2020-05-29

yhy100200 (审核中...)

前往app查看评论内容

#AMIC#

NEJM：ctDNA可能指导II期结直肠癌的后续化疗（DYNAMIC研究）

2022-10-01

yhy100200 (审核中...)

前往app查看评论内容

#AMIC#

JCO：Gemtuzumab Ozogamicin可改善KMT2A重排型AML患儿预后、减少复发！

2021-10-08

yhy100200 (审核中...)

前往app查看评论内容

#AMIC#

Blood：Inotuzumab ozogamicin用于复发/难治性小儿急性淋巴细胞白血病的疗效

2021-12-25

yhy100200 (审核中...)

前往app查看评论内容

#AMIC#

Blood：Getuzumab ozogamicin治疗对NPM1突变AML患者MRD和复发风险的影响

2021-06-26

yhy100200 (审核中...)

前往app查看评论内容

#AMIC#

复发难治性ALL的挽救治疗：低强度化疗联合Inotuzumab Ozogamicin

2019-12-27

yhy100200 (审核中...)

前往app查看评论内容

#AMIC#

美国FDA向Amicus的AT-GAA治疗迟发型庞贝氏病授予了突破性治疗指定

2019-07-15

yhy100200 (审核中...)

前往app查看评论内容

#AMIC#

Amicus的Galafold在美国获批

2018-09-17

yhy100200 (审核中...)

前往app查看评论内容

#AMIC#

！Amicus庞培病疗法获突破性疗法认定

2019-10-15

yhy100200 (审核中...)

前往app查看评论内容

#AMIC#

药明生物祝贺Amicus新一代庞贝氏症疗法获FDA突破性疗法认定

2019-12-24

yhy100200 (审核中...)

前往app查看评论内容

#AMIC#

FDA拒绝加速审批Amicus公司的庞贝病新药AT-GAA

2019-02-10

yhy100200 (审核中...)

前往app查看评论内容

#AMIC#

J Endod：单锥核技术辅以Endosequence Bioceramic封闭剂的非手术根管治疗的临床效果观察

2018-06-10

yhy100200 (审核中...)

前往app查看评论内容

#AMIC#

Amicus Therapeutics法布里病新药Galafold获英国NICE支持批准

2017-01-21

yhy100200 (审核中...)

前往app查看评论内容

#AMIC#

NEJM：Inotuzumab ozogamicin治疗ALL效果显著

2016-12-31

yhy100200 (审核中...)

前往app查看评论内容

#AMIC#

EHA 2016：辉瑞ADC药物inotuzumab ozogamicin治疗CD22阳性急性淋巴细胞白血病（ALL）表现出强劲疗效

2016-09-24

yhy100200 (审核中...)

前往app查看评论内容

#AMIC#

罕见病新药递送！英国NICE批准Amicus公司法布里病新药Galafold

2017-09-30

科室
- - 订阅+
  - 更多科室
工具
服务